JP7409594B2 - 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 - Google Patents

医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 Download PDF

Info

Publication number
JP7409594B2
JP7409594B2 JP2020500810A JP2020500810A JP7409594B2 JP 7409594 B2 JP7409594 B2 JP 7409594B2 JP 2020500810 A JP2020500810 A JP 2020500810A JP 2020500810 A JP2020500810 A JP 2020500810A JP 7409594 B2 JP7409594 B2 JP 7409594B2
Authority
JP
Japan
Prior art keywords
lipid
lipid vesicle
vesicle particles
peptide
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526530A5 (OSRAM
JP2020526530A (ja
Inventor
リーラダー サマトゥール，
ラジカナン ラジャゴパラン，
アースヴァン シャーマ，
ヴァラルマシー カリアペルマル，
ジェネヴィーヴ ウィアー，
マリアンヌ スタンフォード，
アンドレア ペンウェル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovaccine Technologies Inc
Original Assignee
Immunovaccine Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovaccine Technologies Inc filed Critical Immunovaccine Technologies Inc
Publication of JP2020526530A publication Critical patent/JP2020526530A/ja
Publication of JP2020526530A5 publication Critical patent/JP2020526530A5/ja
Application granted granted Critical
Publication of JP7409594B2 publication Critical patent/JP7409594B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020500810A 2017-07-10 2017-11-09 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 Active JP7409594B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530498P 2017-07-10 2017-07-10
US62/530,498 2017-07-10
PCT/CA2017/051336 WO2019010560A1 (en) 2017-07-10 2017-11-09 PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION USING LIPID VESICLE PARTICLES OF A DEFINED SIZE, AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020526530A JP2020526530A (ja) 2020-08-31
JP2020526530A5 JP2020526530A5 (OSRAM) 2020-12-10
JP7409594B2 true JP7409594B2 (ja) 2024-01-09

Family

ID=65000992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500810A Active JP7409594B2 (ja) 2017-07-10 2017-11-09 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用

Country Status (7)

Country Link
US (1) US20200230057A1 (OSRAM)
EP (1) EP3651733A4 (OSRAM)
JP (1) JP7409594B2 (OSRAM)
CN (1) CN111093623A (OSRAM)
AU (1) AU2017423053A1 (OSRAM)
CA (1) CA3069019A1 (OSRAM)
WO (1) WO2019010560A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
SG11202108896UA (en) * 2019-02-15 2021-09-29 Cleveland Clinic Found Vaccine adjuvants and formulations
CA3136066A1 (en) * 2019-04-05 2020-10-08 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant and composition containing same
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US20230348935A1 (en) * 2020-09-24 2023-11-02 Nant Holdings Ip, Llc Vaccine compositions for mucosal immune response
EP4216934A4 (en) * 2020-09-28 2024-11-06 ImmunoVaccine Technologies Inc. LIPID COMPOSITIONS COMPRISING POLYNUCLEOTIDE ANTIGENS

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010180253A (ja) 2004-01-07 2010-08-19 Biomedical Research Models Inc 抗原または免疫原に対する免疫応答を仕立てる方法。
JP2010235464A (ja) 2009-03-30 2010-10-21 Natl Inst Of Radiological Sciences 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法
JP2013530190A (ja) 2010-07-06 2013-07-25 セントロ ド インムノロジア モレキュラー リポソーム中にカプセル化されたスチコリシンに基づくワクチン組成物
JP2014519496A (ja) 2011-05-11 2014-08-14 ナノヴァレント ファーマシューティカルズ，インコーポレイテッド Ａｌｃａｍ細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制
JP2015096505A (ja) 2008-06-05 2015-05-21 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
JP2015522041A (ja) 2012-07-05 2015-08-03 タイワン リポソーム カンパニー リミテッド 関節炎の処置方法
JP2016517423A (ja) 2013-03-15 2016-06-16 キュアポート インコーポレイテッド 脂質ナノ粒子の調製のための方法および装置
WO2017083963A1 (en) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
WO2017097196A1 (zh) 2015-12-08 2017-06-15 正大天晴药业集团股份有限公司 脂质体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906110A (en) * 1959-09-29 Silencing attachment for seamless
KR101102834B1 (ko) * 2010-02-24 2012-01-05 충남대학교산학협력단 신규한 리포좀 제조 방법 및 장치
CN113876945A (zh) * 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
KR102284689B1 (ko) * 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
ES2721325T3 (es) * 2011-11-04 2019-07-31 Nitto Denko Corp Método para producir de manera estéril partículas de lípido-ácido nucleico
CA2994032C (en) * 2015-08-19 2020-08-04 Shanghai Ginposome Pharmatech Co., Ltd. Liposomes with ginsenoside as membrane material and preparations and use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010180253A (ja) 2004-01-07 2010-08-19 Biomedical Research Models Inc 抗原または免疫原に対する免疫応答を仕立てる方法。
JP2015096505A (ja) 2008-06-05 2015-05-21 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
JP2010235464A (ja) 2009-03-30 2010-10-21 Natl Inst Of Radiological Sciences 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法
JP2013530190A (ja) 2010-07-06 2013-07-25 セントロ ド インムノロジア モレキュラー リポソーム中にカプセル化されたスチコリシンに基づくワクチン組成物
JP2014519496A (ja) 2011-05-11 2014-08-14 ナノヴァレント ファーマシューティカルズ，インコーポレイテッド Ａｌｃａｍ細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制
JP2015522041A (ja) 2012-07-05 2015-08-03 タイワン リポソーム カンパニー リミテッド 関節炎の処置方法
JP2016517423A (ja) 2013-03-15 2016-06-16 キュアポート インコーポレイテッド 脂質ナノ粒子の調製のための方法および装置
WO2017083963A1 (en) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
WO2017097196A1 (zh) 2015-12-08 2017-06-15 正大天晴药业集团股份有限公司 脂质体的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta，1993年，Vol.1151，pp.201-215

Also Published As

Publication number Publication date
US20200230057A1 (en) 2020-07-23
WO2019010560A1 (en) 2019-01-17
CN111093623A (zh) 2020-05-01
EP3651733A4 (en) 2021-04-07
CA3069019A1 (en) 2019-01-17
JP2020526530A (ja) 2020-08-31
EP3651733A1 (en) 2020-05-20
AU2017423053A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
JP7103726B2 (ja) 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用
JP6851983B2 (ja) デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
US20200230057A1 (en) Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof
JP2014528955A5 (OSRAM)
US20230000769A1 (en) Oil-in-water emulsion formulations for delivery of active or therapeutic agents
JP2022116265A (ja) 両親媒性化合物、新生抗原及び疎水性担体を含むワクチン組成物、並びにその使用方法
CN101815529A (zh) 包含抗原、两性化合物和疏水载体的组合物及其应用
Khalifa et al. Subunit antigen delivery: emulsion and liposomal adjuvants for next-generation vaccines
WO2024102332A1 (en) Vaccine compositions comprising a neoantigen of kras
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
JP2022116014A (ja) ヒト対象において抗体免疫応答を誘導するために低投与体積ｂ細胞エピトープ組成物を使用する方法
HK40035550A (en) Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
WO2024186646A1 (en) Methods of making lipid adjuvanted compositions
WO2024186623A1 (en) Methods of making dried pharmaceutical compositions
EP4408460A1 (en) Survivin and mage-a9 dual-targeted immunotherapy
Udhayakumar Development and validation of synthetic-virus like vaccines
Trent A modular, multivalent, and multifunctional vaccine platform based on self-assembled peptide amphiphile micelles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200313

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231211

R150 Certificate of patent or registration of utility model

Ref document number: 7409594

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150